mRNA Synthesis Custom Order

mRNA synthesis, also known as in vitro transcription (IVT), is commonly used to synthesize mRNA for specific genes or to make RNA molecules for research purposes. IVT is a process of producing gene RNA by combining RNA polymerase with various elements required for transcription.

1. Cap:

  • Cap consists of a specific nucleotide located at the 5' end of eukaryotic mRNA.
  • Cap is an essential element for protecting mRNA, increasing translation efficiency, and regulating immune responses.
  • Cap-0: It consists of a unique nucleotide called 7-methylguanino (m7G) at the 5’ end of mRNA.
  • Cap-1: In addition to Cap-0, it refers to a structure in which the 2’-OH group of the first nucleotide is replaced with a methyl group.

2. 5’ & 3’ Untranslated Region (UTR):

  • UTR refers to the untranslated region of mRNA. UTRs are located at the 5' end (5' UTR) and 3' end (3' UTR) of mRNA and play an important role in regulating translation efficiency, stability, and localization of mRNA.
  • 5' UTR: Located at the 5' end of the mRNA molecule, preceding the coding region (CDS). The 5' UTR performs the following functions:
    • Translation initiation: The translation initiation complex (eIF4F) binds to determine where translation begins.
    • Modulation of translation efficiency: Certain structural elements within a UTR can increase or decrease translation efficiency.
    • Regulation of mRNA stability: Certain structural elements within the UTR can increase or decrease the stability of the mRNA.
  • 3' UTR: Located at the 3' end of the mRNA molecule, after the coding region (CDS). The 3' UTR performs the following functions:
    • Regulation of mRNA stability: Certain structural elements present within the UTR can increase or decrease the stability of the mRNA.
    • Regulation of mRNA localization: Specific structural elements can regulate the movement of mRNA to specific locations within the cell.
    • Post-translational regulation: Specific elements within the UTR can regulate the degradation, modification, and transport of mRNA after protein translation.

3. Coding Region Sequence (CDS):

  • CDS is the core part that contains genetic information and is the basic unit of protein expression. CDS is expressed as a protein through transcription and translation processes.
  • mRNA consists of four bases (A, U, C, G), and three base sequences (codons) code for specific amino acids. It generally consists of a continuous codon sequence starting with a start codon (ATG) and ending with a stop codon (TAA, TAG, TGA). This contiguous codon sequence is also called Open Reading Frame (ORF).
  • CDS can design DNA sequences based on desired protein sequences and synthesize desired DNA sequences through gene synthesis technology.

4. Poly(A) tail:

  • It refers to a tail in which adenine (A) nucleotides are continuously connected at the 3' end of mRNA.
  • The poly(A) tail protects mRNA from nuclease (RNA-degrading enzyme), preventing degradation of mRNA and increasing its stability.

The ability to produce large quantities of customized mRNA through in vitro transcription (IVT) allows it to be used for a variety of purposes across a range of applications:

  • 1. mRNA vaccine development: This is the fastest growing area with IVT. mRNA encoding viral antigens (foreign molecules that trigger an immune response) can be produced quickly and efficiently through IVT. These mRNA vaccines instruct cells to produce antigens, stimulating the immune system to develop immunity without introducing the entire virus. This method offers several advantages:
    • Faster development: Compared to traditional vaccines, mRNA vaccines can be designed and manufactured much faster and are advantageous for responding to emerging infectious diseases.
    • Safety: Because they do not contain live virus, mRNA vaccines are generally considered safe with minimal side effects.
    • Versatility: mRNA platforms can be easily adapted to target a variety of pathogens by simply modifying the encoded antigen sequence.
  • 2. Gene therapy: IVT has tremendous potential to develop new gene therapies for a variety of genetic diseases.
  • 3. Protein production: Synthetic mRNA can be used for large-scale production of specific proteins in cell-free systems. Applications include:
    • Research applications: Studying protein function, protein-protein interactions, or drug discovery.
    • Production of difficult-to-obtain proteins: Certain proteins may be difficult to isolate from natural sources or may require complex purification processes. IVT provides an alternative way to obtain these proteins for research or therapeutic purposes.
  • 4. Other potential applications: mRNA has additional potential uses in fields such as:
    • Tissue engineering: Stimulating tissue regeneration by delivering mRNA coding for specific growth factors or proteins.
    • Cell reprogramming: Using mRNA to induce changes in cell fate or identity for regenerative medicine applications.
    • Cancer immunotherapy: Designing mRNA vaccines to target cancer antigens or deliver immunostimulatory molecules.

Access the Bioneer homepage (eng.bioneer.com), log in, and follow the form specified on the mRNA synthesis custom order page for Capping, UTR, Poly(A) tail. Please select the availability and type, fill in the Coding Region Sequence, etc. and submit. After confirmation, you will receive detailed guidance on mRNA synthesis.

The optimal RNA transcript size for mRNA synthesis service is 100 to 5,000 nt. If you require a length other than this, service will be provided after consultation.

Template DNA Samples must be sent in a volume of 10 μl or more (at least 1 μg of DNA) at a concentration of 100 to 200 ng/μl.

Please accurately enter your organization and client name in the box, and deliver the sample through the affiliated delivery company below.

Sending address: Bioneer R&A Farm Co., Ltd., 8-11 Munpyeongseo-ro, Daedeok-gu, 34302 Daejeon, Republic of Korea.

Shipping costs: We are responsible for the cost regardless of the number of templates. If the service becomes difficult due to incorrect sample delivery, 50% of the final billing amount will be charged as a set-up charge. When delivering samples, please be sure to check and send carefully.

It's possible. For further information, please contact mrnaorder@bioneer.co.kr.

For 5’ Cap, you can choose Cap-0 or Cap-1. The 3’ poly(A) tail can be selected as 111 nt (105 nt poly-A with 6 nt linker in the middle).

Custom 5’ or 3’ UTR modification is possible. Alternatively, you can choose Bioneer 5’ or 3’ UTR.

If you would like to manufacture RNA-LNP in conjunction with the lipid nanoparticle (LNP) service, please contact us.

The synthesized mRNA is provided in a freeze-dried state, and electrophoresis results and absorbance measurement results using Nanodrop are included.

After the successful entry of the COVID-19 mRNA vaccine into the market, active research is underway for the development of mRNA vaccines and therapeutics. BIONEER provides custom mRNA development process through extensive research optimizing in vitro transcription (IVT) and purification for stable and efficient mRNA synthesis. BIONEER mRNA synthesis service offers a variety of options to provide tailored mRNA solutions to suit your needs.

Request a quote

Inquire
Cat. No.
mrna-synthesis-inquire

Overview

BIONEER provides various types of mRNA using our advanced mRNA synthesis technology. For mRNA synthesis, you can either provide the DNA template or it can be linked with our in-house Gene Synthesis Service.

Our mRNA Synthesis Service is categorized into two options: Standard mRNA Synthesis Service and Complete mRNA Synthesis Service. The standard service provides only the RNA coding sequence, with optional choices of 5' cap and 3' poly (A) tail. Complete service offers not only the RNA coding sequences but also includes 5' cap, 3' poly (A) tail, and 5' & 3' UTR. Depending on your experimental designs, you may select the service that suits your needs.

RNA coding sequence 5' cap 3' poly (A) tail 5' & 3' UTR
Standard mRNA Synthesis O Option Option X
Complete mRNA Synthesis O O O O

The ordered mRNA is shipped in a lyophilized (freeze-dried) form, along with gel electrophoresis and NanoDrop absorbance data.

Features and Benefits

  • Customize your desired mRNA with 5' or 3' poly (A) tailing modification options according to your experimental designs.

  • Microgram to milligram scale mRNA production

  • Modified rNTPs to suit your application needs

  • Premade reporter gene (eGFP, mCherry, Luciferase) mRNA is available at reasonable prices.

  • RNA-Lipid nanoparticle (LNP) service is available.

Experimental Data

Figure1. Electrophoresis results of the RNA product
Ctrl 3 months 6 months 12 months
Amount(μg) 11.3 11.4 11.2 11.4
A260/A280 1.98 2.00 1.99 1.99
A260/A230 2.44 2.41 2.43 2.45
Figure2. Stability test results of the lyophilized RNA product
Figure 3. GFP expression in Huh-7 cells by transfecting GFP mRNAs.
  Negative control : Uncapped mRNA, Positive control : CleanCap (Trilink) mRNA,
  Bioneer’s VCE : Cap-0 and Cap-1 mRNAs capped by Bioneer’s vaccinia capping enzyme
Copyright© 2024 BIONEER CORPORATION. All rights reserved.